This Peptide will Revolutionize Health!

Physionic

Apr 30, 2026

Episode description

JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]
Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2

HEALTH AUTONOMY [COURSE]
Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy

JOIN THE COMMUNITY
Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2

EMAIL LIST
1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6

HIRE ME FOR CONSULTING:
Consulting: https://bit.ly/3dmUl2H

Created with Biorender

0:00 - Introduction
0:25 - A Three Headed Dragon
1:05 - Triple Peptide vs Dual Peptide
2:50 - A Breathtaking Advantage
5:50 - Recognize this Name?
6:23 - Is this stuff Safe?

References
[Study 713] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972.

Funding/Conflict: Public Funding: From the study, no public funding was reported; Non-Profit Funding: From the study, no non-profit funding was reported; Industry Funding: From the study, the trial was funded by Eli Lilly; Conflicts of Interest: From the study, several coauthors were Eli Lilly employees, and the sponsor designed and oversaw the trial, conducted site monitoring, data collation, and data analysis, with the last author also an employee of the sponsor.

[Study 714] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2.

[Study 715] Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247. doi:10.1016/j.cmet.2022.07.013.

Funding/Conflict: Public Funding: From the study, no public funding was reported; Non-Profit Funding: From the study, no non-profit funding was reported; Industry Funding: From the study, the funder was Eli Lilly and Company, which provided the study drug and was involved in study design, data collection, data analyses, data interpretation, and writing of the report. Conflicts of Interest: From the study, A.J.S. reported stock options, extensive consulting, institutional grant support, and royalties; L.M.K. reported scientific and medical consulting roles; J.P.F. reported research funding, consulting fees, speaker bureau, travel support, and advisory/consulting roles with multiple companies; and M.L.H., B.B., C.H., K.J.M., A.H., Q.W., Y.D., N.C.S., and M.K.T. were employees and shareholders of Eli Lilly and Company.

[1] Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(6):482-493. doi:10.1016/S2213-8587(25)00027-0

Please use the following link to submit your critique: https://bit.ly/PhysionicCritique

Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.

Mindsip insights from this episode:

Manage gastrointestinal side effects of peptide therapies

The side effects are reportedly similar to other peptides in its class, like semaglutide, and are primarily gastrointestinal issues, with serious effects being very rare.

#peptides

#side-effects

Preserve muscle while achieving fat loss with peptide therapy

Despite causing greater fat loss, the peptide does not appear to cause any more lean mass loss than what would be expected from calorie restriction alone.

#muscle

#peptides

Leverage Retatrutide for significant weight loss reduction

A new peptide, Retatrutide (formerly LY3437943), has shown the potential to cause a 30-40% reduction in body weight, significantly outperforming current options.

#peptides

#weight-loss

Achieve weight loss without metabolic slowdown

Unlike typical calorie restriction which slows metabolism, this peptide allows for weight loss while maintaining a normal metabolic rate, preventing the common dieting plateau.

#metabolism

#weight-loss

Leverage triple-action peptide to regulate insulin, metabolism, and appetite

This peptide is uniquely designed to bind to three different receptors, simultaneously influencing insulin release, metabolism, and appetite signals from the brain.